130 likes | 484 Views
Tigecycline Approved by EMEA, 2006. Glycylcycline (relative minocycline) Intravenous only licenced for complicated skin and skin structure infections ( CSSSI ) and complicated intra-abdominal infection ( IAI ) dosage for complicated SSSI and IAI: 100mg followed by 50mg 12 hourly. EUCAST view.
E N D
Glycylcycline (relative minocycline) • Intravenous only • licenced for complicated skin and skin structure infections (CSSSI) and complicated intra-abdominal infection (IAI) • dosage for complicated SSSI and IAI: 100mg followed by 50mg 12 hourly
EUCAST view • clinically useful activity against staphylococci, β-haemolytic streptococci, enterococci, E. coli, Klebsiella spp, and several other Enterobacteriaceae. • promising but unproven activity against Acinetobacter and several anaerobes which have not received breakpoints. • EUCAST does not consider tigecycline active against Pseudomonas aeruginosa and some species of Enterobacteriacae (Proteus, Morganella and Providencia) which have not received breakpoints.
Tigecycline activity www.eucast.org